Rational Design, Synthesis, In Vitro, and In Silico Studies of Dihydropyrimidinone Derivatives as β-Glucuronidase Inhibitors

Figure 1

Identified leads for β-glucuronidase inhibition. (a) IC₅₀ = 7.17 ± 0.30 μM, (b) IC₅₀ = 7.62 ± 0.04 μM, (c) IC₅₀ = 2.14 ± 0.03 μM, (d) IC₅₀ = 2.26 ± 0.06 μM, (e) IC₅₀ = 1.20 ± 0.01 μM, (f) IC₅₀ = 1.60 ± 0.10 μM, (g) IC₅₀ = 9.38 ± 0.15 μM, (h) IC₅₀ = 0.35 ± 0.09 μM, (i) new design scaffold.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)